Related Experiment Video

Updated: Jun 17, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

911

HTB50-2 Inhibits Growth and Migration of Triple-negative Breast Cancer via FOSL2/FOXC1 Signaling Axis and Subsequent

Na Liu1, Wen-Ying Yin1, Wen-Qi Duan1

  • 1School of Biological Science and Technology, University of Jinan, Jinan, 250022, China.

Current Medicinal Chemistry
|August 12, 2024
PubMed
Abstract

Insights

14β-hydroxy-3β-(β-D-Glucopyranosyloxy)-5α-bufa-20,22-dienolide (HTB50-2) induces ferroptosis in Triple-Negative Breast Cancer (TNBC) cells, inhibiting tumor growth. This natural compound targets the FOSL2/FOXC1 signaling pathway for potential TNBC therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Ferroptosis induction is a promising cancer therapy strategy.
  • Natural products are gaining interest for cancer treatment.
  • Triple-Negative Breast Cancer (TNBC) remains a therapeutic challenge.

Purpose of the Study:

  • To evaluate the anticancer efficacy of HTB50-2 in TNBC.
  • To elucidate the underlying mechanisms of HTB50-2's action.
  • To explore the role of FOSL2 and FOXC1 in HTB50-2-mediated ferroptosis.

Main Methods:

  • Sulforhodamine B assay and cell migration assays (wound healing, transwell).
  • In vivo studies using orthotopic transplantation in BALB/c mice.
  • Transcriptome sequencing, Western blot, and immunohistochemistry to analyze FOSL2 and FOXC1.

Main Results:

  • HTB50-2 effectively induced ferroptosis in TNBC cells.
  • HTB50-2 inhibited tumor growth in vivo by promoting ferroptosis.
  • FOSL2 was identified as a key mediator of HTB50-2-induced ferroptosis, regulating FOXC1.

Conclusions:

  • HTB50-2 exhibits anti-cancer properties in TNBC through ferroptosis induction.
  • The FOSL2/FOXC1 signaling pathway is crucial for HTB50-2's therapeutic effect.
  • HTB50-2 demonstrates significant potential for TNBC treatment.
Keywords:
CGsFOSL2FOXC1.TNBCferroptosismigration

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.5K
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.3K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K